Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GALR2 | O43603 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23648006 | 0.80 | MAPT (0.40) | NPSR1MAPTCA1CA2CA9 | |
| SCHEMBL28878765 | 0.78 | GRIN2D (0.45) | NPSR1MAPTCA1CA2CA9 | |
| SCHEMBL9674482 | 0.77 | HDAC1 (0.50) | MAPTCA1CA2CA9HTT | |
| SCHEMBL1425030 | 0.77 | MAPT (0.55) | NPSR1MAPTCA1CA2CA9 | |
| SCHEMBL23579735 | 0.76 | MAPT (0.40) | NPSR1MAPTCA1CA2CA9 | |
| SCHEMBL30748250 | 0.75 | NPSR1 (0.50) | NPSR1MAPTCA1CA2CA9 | |
| SCHEMBL3251790 | 0.75 | NPSR1 (0.50) | NPSR1MAPTCA1CA2CA9 | |
| SCHEMBL9232481 | 0.75 | MAPT (0.54) | NPSR1MAPTCA1CA2CA9 | |
| SCHEMBL4652737 | 0.75 | MAPT (0.54) | NPSR1MAPTCA1CA2CA9 | |
| SCHEMBL16427650 | 0.75 | SMN1; SMN2 (0.41) | NPSR1MAPTCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528127-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7485635-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2009-02-03 | — | — | US | disclosed |
| US-7473689-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2009-01-06 | — | — | US | disclosed |
| US-7435730-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2008-10-14 | — | — | US | disclosed |
| US-20070135420-A1 | e.g. Methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-pyrro[1,2-a][1,4]benzodiazepin-4-yl]propanoate; GABAA (gamma aminobutiric acid) receptor antagonist; sedative-hypnotic, anxiolytic, muscle relaxant and anticonvulsant; anesthesia | CENES LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135419-A1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135421-A1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070093475-A1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
| US-7160880-B1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| EP-1183243-B1 | SHORT-ACTING BENZODIAZEPINES | CENES LTD (GB) | 2006-02-08 | — | — | EP | disclosed |
| EP-1183243-A1 | SHORT-ACTING BENZODIAZEPINES | GLAXO GROUP LIMITED (GB) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069836-A1 | SHORT-ACTING BENZODIAZEPINES | GLAXO GROUP LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
| US-4326009-A | Polymeric particulate carrier | ROYER GARFIELD P | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093475-A1 | Short-acting benzodiazepines | GABRA5, GABRA1, GABRA6 | NPSR1 70/4885MAPT 1229/4885CA1 2879/4885 |
| US-20070135420-A1 | e.g. Methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-pyrro[1,2-a][1,4]benzodiazepin-4-yl]propanoate; GABAA (gamma aminobutiric acid) receptor antagonist; sedative-hypnotic, anxiolytic, muscle relaxant and anticonvulsant; anesthesia | GABRA1, GABRA2, GABRA6 | NPSR1 221/4885MAPT 3137/4885CA1 711/4885 |
| US-20070135419-A1 | Short-acting benzodiazepines | GABRA5, GABRA1, GABRA6 | NPSR1 70/4885MAPT 1229/4885CA1 2879/4885 |
| US-20070135421-A1 | Short-acting benzodiazepines | GABRA5, GABRA1, GABRA6 | NPSR1 70/4885MAPT 1229/4885CA1 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.